drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-NK)
drug_description
Allogeneic, gene-engineered natural killer cell therapy expressing a chimeric antigen receptor targeting Trop-2 (TACSTD2) to enable antigen-specific NK activation and cytotoxicity against Trop2-positive tumor cells in relapsed/refractory NSCLC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, gene-engineered natural killer cells expressing a chimeric antigen receptor for Trop-2 (TACSTD2) recognize Trop-2–positive tumor cells and induce antigen-dependent NK activation, resulting in perforin/granzyme-mediated cytotoxicity and cytokine release to kill Trop-2–expressing NSCLC cells.
drug_name
Anti-Trop2 CAR-NK cell
nct_id_drug_ref
NCT06454890